Institut Pasteur
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases research at Institut Pasteur
Clinical studies in this area focus on hidradenitis suppurativa, a chronic inflammatory condition affecting the skin and surrounding tissue. The research is designed to evaluate whether a tailored antibiotic approach can improve disease control compared with standard treatment.
- Hurley stage 2 active hidradenitis suppurativa
- Testing a new treatment strategy for better symptom management and clinical response
- Comparing an adapted antibiotic approach with a conventional therapy
This work reflects a strong interest in improving care for patients with persistent skin inflammation through more effective treatment options.
Virus Diseases research in infectiology
The site is also conducting research on mpox, with a focus on prevention and immune protection after vaccination. These trials are assessing whether a booster dose can strengthen the body’s immune response and support better protection against infection.
- Prevention of monkeypox (mpox) infection
- Evaluating vaccine booster effectiveness for immune response and safety
- Studying protection strategies after primary vaccination
At Institut Pasteur, this line of research highlights ongoing efforts to improve viral disease prevention and support public health preparedness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Institut Pasteur1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Pasteur
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 2 Randomized, Open-Label Trial of Intradermal vs. Subcutaneous MVA-BN Vaccine Booster for Mpox Immunogenicity in Previously Vaccinated Individuals | The Public Health Agency Of Sweden | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ceftriaxone | 1 | Unknown | 2025-05-22 | 2025-05-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.